UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 285

Sortiert nach

Recovery of Posterior Communicating Artery Aneurysm-Induced Oculomotor Palsy after Coiling

American journal of neuroradiology : AJNR, 2008-05, Vol.29 (5), p.988-990

2008

Volltextzugriff (PDF)

Incidence of central nervous system involvement in chronic lymphocytic leukemia and outcome to treatment

Journal of neurology, 2008-06, Vol.255 (6), p.828-830

2008

Volltextzugriff (PDF)

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

British journal of cancer, 2015-07, Vol.113 (2), p.226-231

2015

Volltextzugriff (PDF)

Incidence of central nervous system involvement in chronic lymphocytic leukemia and outcome to treatment

Journal of neurology, 2008-06, Vol.255 (6), p.828-830

2008

Volltextzugriff (PDF)

IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

Neuro-oncology (Charlottesville, Va.), 2014-07, Vol.16 (suppl 3), p.iii8-iii9

2014

Volltextzugriff (PDF)

Unilateral palsy of all cranial nerves (Garcin syndrome) in a patient with rhinocerebral mucormycosis

Journal of neurology, 2003-04, Vol.250 (4), p.506-507

2003

Volltextzugriff (PDF)

Antisaccades and remembered saccades in mild traumatic brain injury

Journal of neurology, 2000-03, Vol.247 (3), p.179-182

2000

Volltextzugriff (PDF)

Hemangioblastomatosis in a patient with von Hippel-Lindau disease

Journal of neuro-oncology, 2007-04, Vol.82 (2), p.163-164

2007

Volltextzugriff (PDF)

Two exceptional phenomena in an anaplastic oligo-astrocytoma

Journal of neuro-oncology, 2006-06, Vol.78 (2), p.197-197

2006

Volltextzugriff (PDF)

P14.31 Between hospital variation in timings to multidisciplinary glioblastoma care in the Dutch Brain Tumor Registry

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii44-ii44

2021

Volltextzugriff (PDF)

P14.40 Trends in distribution of glioblastoma care and patient’s travel distance; results from the Dutch Brain Tumor Registry

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii46-ii46

2021

Volltextzugriff (PDF)

AT-55 FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v20-v21

2014

Volltextzugriff (PDF)

P21.05 Quality criteria for glioma care: development of clinical indicators

Neuro-oncology (Charlottesville, Va.), 2016-10, Vol.18 (suppl_4), p.iv82-iv82

2016

Volltextzugriff (PDF)

O10.05 FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS

Neuro-oncology (Charlottesville, Va.), 2014-09, Vol.16 (suppl 2), p.ii24-ii24

2014

Volltextzugriff (PDF)

Exponential Krylov time integration for modeling multi-frequency optical response with monochromatic sources

Journal of computational and applied mathematics, 2018-10, Vol.340, p.474-485

2018

Volltextzugriff (PDF)

P01.037 Quality criteria for glioma care, use in clinical practice: results of a national survey

Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (suppl_3), p.iii236-iii237

2018

Volltextzugriff (PDF)

P04.24 Apparent diffusion coefficient histogram analysis in recurrent glioblastoma predicts overall survival after the first course of bevacizumab and lomustine

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (suppl_3), p.iii45-iii46

2017

Volltextzugriff (PDF)

P01.12 Stability of actionable mutations in primary and recurrent glioblastomas

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (suppl_3), p.iii25-iii26

2017

Volltextzugriff (PDF)

NIMG-13. RADIOLOGICAL RESPONSE ASSESSMENT IN THE ERA OF BEVACIZUMAB: RANO OR VOLUMETRY? A REPORT FROM THE BELOB TRIAL

Neuro-oncology (Charlottesville, Va.), 2016-11, Vol.18 (suppl_6), p.vi126-vi126

2016

Volltextzugriff (PDF)

GE-10 IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v98-v98

2014

Volltextzugriff (PDF)

O10.05 FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS

Neuro-oncology (Charlottesville, Va.), 2014-09, Vol.16 (suppl 2), p.ii24-ii24

2014

Volltextzugriff (PDF)

O10.05FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS

Neuro-oncology (Charlottesville, Va.), 2014-09, Vol.16 (Suppl 2), p.ii24-ii24

2014

Volltextzugriff (PDF)

Aromatherapy and massage

Nursing standard, 1990-08, Vol.4 (48), p.43

Hanse, M

1990

Volltextzugriff (PDF)

Depression, the Val66Met polymorphism, age, and gender influence the serum BDNF level

Journal of psychiatric research, 2012-09, Vol.46 (9), p.1118-1125

2012

Volltextzugriff (PDF)

1 – 25 von 285

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(162)
Mit Volltextzugriff
(269)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Recovery of Posterior Communicating Artery Aneurysm-Induced Oculomotor Palsy after Coiling

Incidence of central nervous system involvement in chronic lymphocytic leukemia and outcome to treatment

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

Incidence of central nervous system involvement in chronic lymphocytic leukemia and outcome to treatment

IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

Unilateral palsy of all cranial nerves (Garcin syndrome) in a patient with rhinocerebral mucormycosis

Antisaccades and remembered saccades in mild traumatic brain injury

Hemangioblastomatosis in a patient with von Hippel-Lindau disease

Two exceptional phenomena in an anaplastic oligo-astrocytoma

P14.31 Between hospital variation in timings to multidisciplinary glioblastoma care in the Dutch Brain Tumor Registry

P14.40 Trends in distribution of glioblastoma care and patient’s travel distance; results from the Dutch Brain Tumor Registry

AT-55 FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS

P21.05 Quality criteria for glioma care: development of clinical indicators

O10.05 FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS

Exponential Krylov time integration for modeling multi-frequency optical response with monochromatic sources

P01.037 Quality criteria for glioma care, use in clinical practice: results of a national survey

P04.24 Apparent diffusion coefficient histogram analysis in recurrent glioblastoma predicts overall survival after the first course of bevacizumab and lomustine

P01.12 Stability of actionable mutations in primary and recurrent glioblastomas

NIMG-13. RADIOLOGICAL RESPONSE ASSESSMENT IN THE ERA OF BEVACIZUMAB: RANO OR VOLUMETRY? A REPORT FROM THE BELOB TRIAL

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

GE-10 IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

O10.05 FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS

O10.05FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS

Aromatherapy and massage

Depression, the Val66Met polymorphism, age, and gender influence the serum BDNF level

Suchergebnisse filtern